Innovation / 03.06.2021
Eckert & Ziegler and Telix Pharmaceuticals Enter Co-Promotion Agreement for Prostate Cancer Diagnostic in the United States
Eckert & Ziegler (ISIN DE0005659700, TecDAX) and Telix Pharmaceuticals (Telix) will cooperate closely in the commercialization of GalliaPharm® (68Ge/68Ga Generator) and investigational product Illuccix® (Kit for the preparation of Ga-68 PSMA-11 injection) in the United States. An agreement to this effect has now been signed by the two companies. Illuccix® is a preparation for imaging prostate cancer by positron emission tomography (PET) and is currently under review for regulatory approval in the United States and multiple markets worldwide.
Eckert & Ziegler and Telix will expand their existing collaboration to further develop access to Ga-68 supply in the United States. The parties will both promote the combination of GalliaPharm® and Illuccix® to national radiopharmacy networks, commercial and hospital-based nuclear pharmacies, and other target institutions.
"After previously being granted distribution rights for Germany, our home market, the latest collaboration marks another important milestone for our 68Ga generator GalliaPharm® and our nuclear medicine activities”, explained Dr Harald Hasselmann, Eckert & Ziegler Executive Director and responsible for the Medical segment. “We are pleased to have Telix as a partner and to be able to jointly provide leading edge diagnostic products to prostate cancer patients in the USA.”
“This important cooperation between EZAG and Telix sales teams is highly complementary to our efforts in rolling out 68Ga-PSMA imaging across the US. Subject to FDA approval, we will together raise awareness of this state-of-the-art imaging modality and facilitate coast-to-coast access for US men living with prostate cancer.”, added Telix Americas President Dr Bernard Lambert.
Following regulatory approval, Illuccix® will be offered as a cold kit preparation for the diagnosis of prostate cancer. For this purpose, Illuccix® enables PSMA-11 to be radio-labelled with the radionuclide 68Ga directly before injection by medical personnel. After preparing the radiopharmaceutical and injecting it into the patient, sites exhibiting prostate cancer are localized and imaged via the presence of the prostate-specific membrane antigen.,
Prostate cancer is the most common type of cancer in men in the United States, with approximately 210,000 cases in 2020, a significantly higher incidence than either lung cancer (116,000 new cases) or bowel cancer (82,000 new cases). Prostate cancer was also the second most common cause of cancer death in men, with over 32,000 men dying from the disease in the United States in 2020. More than 812,000 American men were estimated to be living with prostate cancer in 2020.
 Fendler W et al. JAMA Oncol. 2019; 5(6): 856-863.
 Hofman M et al. The Lancet. 2020; 395: 1208-1216.
 IARC Global Cancer Observatory, 2020.
About Eckert & Ziegler
Eckert & Ziegler Strahlen- und Medizintechnik AG with around 800 employees, is one of the world's largest providers of isotope-related components for nuclear medicine and radiation therapy. The company offers services for radiopharmaceuticals at its worldwide locations, from early development to commercialization. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.
About Telix Pharmaceuticals
Telix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com and follow Telix on Twitter (@TelixPharma) and LinkedIn.
Telix's lead investigational product, Illuccix® (TLX591-CDx) for prostate cancer imaging, has been accepted for filing by the U.S. FDA, and is under priority evaluation by the Australian Therapeutic Goods Administration (TGA). Telix is also progressing marketing authorisation applications for Illuccix® in the European Union and Canada. None of Telix's products have received a marketing authorisation in any jurisdiction.
Telix Pharmaceuticals Contact:
Dr. Stewart Holmstrom, Investor Relations
Suite 401, 55 Flemington Road, North Melbourne, VIC 3051, Australia
News Buch Berlin
Disease genes help early brain development
If the cerebral hemispheres of the forebrain fail to divide properly in an unborn child, this results in holoprosencephaly. An MDC team led by Annette Hammes has discovered candidate genes that can po...more ...
Dr. Michael Frieser is named new Administrative Director of the Berlin Institute of Health at Charité (BIH)
He succeeds Andrea Runow, who has held the post since January 1, 2019, and is now retiring. Dr. Michael Frieser, 55, who currently heads the Administration Division at the Paul-Ehrlich-Institut in Lan...more ...
Johanna Quandt-Professorship for Kathrin de la Rosa
Stiftung Charité Foundation and the Berlin Institute of Health at the Charité are continuing their format for recruiting outstanding female scientists. MDC researcher Kathrin de la Rosa is among the f...more ...
Events Buch Berlin
Bewegungstag im Garten des Bürgerhauses
Boule, XXL-Schach, Tanz der Generationen, Gleichgewichtstraining, Zirkeltraining, Federball, und vieles mehr.more ...
Fahrradkodierungsaktion der Polizei und Fahrradcheck
Das Präventionsteam des Polizeiabschnittes 14 führt auf dem Campus Berlin-Buch eine kostenlose, öffentliche Fahrradcodierung durch.more ...